Many cardiovascular diseases and disorders in the heart leads patients to use devices that would replace the heart or at least the left ventricle. Such pumps are effective, however they cause a great deal of problems in terms of malfunctions and infections.
Yet a recent study conducted by a team from Cleveland Clinic-led has found and developed an antibiotic that can be absorbed through envelopes which can reduce or prevent the infections. The study led by associate section head of cardiac electrophysiology at Cleveland Clinic, Dr. Khaldoun Tarakji, was discussed in the American College of Cardiology’s 68th Annual Scientific Session.
He discussed how 1.7 million patients worldwide, use electronic pumps inside their body for heart disorders. A huge percentage from these patients suffer from infections which might lead to more irreversible complications. Their new developed antibiotic has shown results to reduce the rate of infection by almost 40%.
The study and results were published in the New England Journal of Medicine and is expected to be discussed further in the European Heart Rhythm Association 2019 Congress.
According to Dr. Khaldoun, he stated in the conference, “While the risk of major infections is low, when they do occur, they can be devastating for patients, resulting in invasive procedures, device removal, prolonged hospital stays and potentially death. Other than the use of antibiotics right before the device procedures, this is the first intervention proven to reduce the risk of infection in a randomized clinical trial of this magnitude.”